RIVANNA®, developers of imaging-based medical solutions, announced that they have received funding totaling $30.5 million over 39 months from early execution of an option by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The funding …

Virginia Bio and its member companies Ampel BioSolution, Canon Virginia Inc., City of Virginia Beach, CytoRicovery, LifeNet Health, Marsh McLennan Agency, PAK Biosolutions, and ReAlta Life Sciences, are recognized as the 2023 Top Virginia Employers for Interns! Read more about this award that recognizes companies and organizations that foster talent development in Virginia in the article below.   …

Tympanogen, a medical device company based in the Biotech Park of Richmond, VA, was awarded a $3.23 million Small Business Innovation Research (SBIR) grant from the National Institute on Deafness and Other Communication Disorders (NIDCD). This Commercialization Readiness Pilot (CRP) Program grant, a continuation of a prior Direct-to-Phase II grant, will support the pivotal clinical …

Innovative antimicrobial solutions provider Cupron®, doing business as Cupron Performance Additives, announces expanded functionality for its recently introduced antimicrobial platform technology Cupron Sinerji™.  Initially engineered as a copper-based formulation, Cupron® has now extended Cupron Sinerji’s  performance, cost, and color advantage to all metal ion chemistries commonly used for antimicrobial purposes.  Specifically, Cupron’s new platform technology …

The Greater Richmond Partnership (“GRP”) has hired Kiryako Sharikas to join the team as Business Development Manager – Life Sciences. Sharikas will focus on targeting life science and pharmaceutical companies interested in expanding to the Richmond Region. “Kiryako’s experience in marketing will translate well as he markets the region as the #1 mid-sized location in …

Kaléo, a privately-held U.S. pharmaceutical company, today announced their selection by the U.S. Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) to develop a reconstitution auto-injector device that delivers atropine, the Reconstitution Auto-Injector Device …